Researchers developed a novel gene therapy platform that successfully restored muscle function in preclinical models of Duchenne muscular dystrophy by delivering full-length mRNA of the DMD gene via engineered extracellular vesicles. The treatment showed improved muscle strength, endurance, and function without serious side effects.
Researchers at Sanford Burnham Prebys have developed a new method to generate more and potent skeletal muscle progenitor cells. The study found that blocking the activity of Janus kinase 2 (JAK2) yields a twofold increase in cell yield, while also delivering more mature and effective cells for regenerative medicine treatment.
Scientists have discovered that MYOD protein can act as a gene silencer, clearing out old 'furniture' to reset the cell's identity. This finding challenges dogma and opens up new avenues for understanding cellular reprogramming and regenerative medicine therapies.
A new study suggests that marbling of fat inside muscles is a strong indicator of poor health, including obesity, Type 2 diabetes, and neuromuscular disorders. The research found that intramuscular fat acts as a physical barrier obstructing muscle healing and regeneration.
The study found disordered kidney metabolism contributes to DM1 symptoms, including muscle weakness and impaired energy use. The kidney is identified as a site of underlying cell dysfunction contributing to the disease.
A new study reveals a promising therapy using antimiRs to treat myotonic dystrophy type 1 (DM1), a genetic disorder caused by abnormally high CTG repeats in the DMPK gene. The treatment increased MBNL1 levels and improved muscle cell functions, reducing disease symptoms.
Researchers have discovered a gene responsible for some inherited retinal diseases, which damage the retina and threaten vision. The study identified the UBAP1L gene as a cause of different forms of retinal dystrophy, including maculopathy and cone-rod dystrophy, affecting central and night vision.
Researchers at UCL Institute of Ophthalmology have revealed the molecular mechanisms behind FECD, a leading cause of vision loss in older adults. The study found that extreme genetic instability plays a key role in the disease's progression.
Researchers at Karolinska Institutet successfully used gene therapy to improve vision in 11 out of 12 patients with Bothnia dystrophy, a form of hereditary blindness. The treatment involved injecting a specially designed virus under the retina, which produced normal protein and restored visual function.
Researchers have developed three new cellular models of myotonic dystrophy type 1 that accurately represent the clinical diversity of the disease. The models show great heterogeneity in genetic expansion and molecular alterations, making them suitable for studying pathophysiology and testing therapeutic options.
A research team from Université Laval has identified a method to save corneal cells from death using healthy mitochondria, reducing mortality rates from 60% to 10%. This approach demonstrates high therapeutic potential for mitochondrial injection, which could maintain vision without transplantation if diagnosed at an early stage.
Researchers at Massachusetts General Hospital developed a genetic therapy to correct myotonic dystrophy in mice by targeting the abnormal splicing of the Clcn1 gene. The treatment restored muscle strength and corrected muscle stiffness, reversing muscle fiber type transitions.
Researchers found that platelet depletion increased amyloid plaque size and neuronal damage in APP-PS1 mice. However, platelets may have a beneficial role in limiting plaque growth and attenuating neuritic dystrophy at advanced stages of Alzheimer's disease.
A study using a mouse model of myotonic dystrophy found that GABA receptor sensitivity is linked to the disorder's central nervous system symptoms, including excessive daytime sleepiness. The researchers suggest that drugs like flumazenil, which counteract benzodiazepines, may work against DM's prolonged sleep and fatigue.
Researchers at the University of Maine used zebrafish to test the effectiveness of neuromuscular electrical stimulation (NMES) on muscle strength and structure. The study found that only one NMES regimen, endurance neuromuscular stimulation (eNMES), improved muscle health when combined with an antioxidant and a specific receptor.
A clinical trial at UC Davis Health showed that cellular therapy offers promise for patients with late-stage Duchenne muscular dystrophy, stopping deterioration of upper limb and heart functions. The therapy appears to be safe and effective in improving skeletal muscle and cardiac function.
Researchers at EPFL's School of Life Sciences discovered that blocking sphingolipid synthesis can reverse the symptoms of Duchenne muscular dystrophy, including loss of muscle function and inflammation. This study identifies sphingolipid inhibition as a potential treatment for muscular dystrophies.
The Nixon Visions Foundation has given a significant gift to support studies of the PRPH2 gene linked to macular dystrophy and boost stem cell research aimed at developing early diagnosis and a cure for this devastating genetic eye disease. Researchers hope to make a tremendous impact on people with this inherited eye disease.
Researchers at the University of Oregon used CRISPR-Cas9 gene editing to target a specific mutation causing Fuchs' corneal dystrophy, preserving endothelial cell density and function. The study lays the groundwork for future research on using this technique to treat genetic disorders in post-mitotic cells.
Researchers have identified a new blindness gene, IFT122, associated with inherited retinal dystrophy in dogs. The discovery has significant implications for understanding the genetic background of the disease and developing novel treatments.
Researchers from TalTech have made a groundbreaking discovery linking CTG repeat expansion to Fuchs' corneal dystrophy, a common eye disease affecting millions. The study reveals changes in TCF4 expression levels in patients with the disease, paving the way for potential treatment strategies.
Researchers demonstrate that one dose of RNA-targeting CRISPR-Cas9 gene therapy can nearly completely reverse symptoms in a mouse model of myotonic dystrophy, reducing toxic RNA buildup by over 50%. This approach holds promise for treating other genetic diseases caused by repetitive RNA buildup.
Researchers at the University of Nottingham have discovered a potential treatment for myotonic dystrophy by inhibiting the CDK12 molecule. The study found that inhibiting this molecule reduces the symptoms of the condition, suggesting a possible route to therapy.
A study published in Developmental Cell reveals that myotonic dystrophy's genetic abnormalities lead to the overproduction of an alternative-splicing factor that regulates protein processing. This triggers abnormal splicing of proteins essential for heart cell function, causing cardiac conduction defects.
Jayne S. Weiss, MD, has been awarded the 2020 Castroviejo Award for her outstanding work on corneal dystrophies, particularly Schnyder corneal dystrophy. Her research focuses on genetic mapping and pathophysiology of corneal diseases, making significant contributions to the field.
Researchers have successfully developed and tested a gene therapy approach using CRISPR-Cas9 technology to treat Steinert's myotonic dystrophy, a devastating neuromuscular disease. The study showed that the expanded CTG triplet repeat in the DMPK gene was 'cut' and removed from the gene, reducing toxic RNA aggregates in muscle cells.
Researchers at Scripps Research have developed a potential drug that targets the genetic defect causing myotonic dystrophy type 1, a disease affecting 1 in 2,500 people. The therapy, called Cugamycin, improves muscle defects without harming healthy gene transcripts.
A new editorial and free resource clarify corneal dystrophy diagnoses based on corrected medical literature, with the International Committee for Classification of Corneal Dystrophies providing an updated standard classification. The IC3D nomenclature has become internationally accepted.
Researchers have identified genetic factors that cause congenital myotonic dystrophy, a debilitating muscle disorder. They developed specialized mouse models to test potential drug therapies and found severe RNA misprocessing as a major cause of the disease.
Researchers discovered three novel genetic mutations associated with Fuchs endothelial corneal dystrophy, increasing the number of known risk factors fourfold. The study also revealed sex-specific differences in genetics and found that these genes can predict disease risk with approximately 78% accuracy.
Researchers found that treatments don't fit a 'one size fits all' model for patients with myotonic dystrophy type 1. Targeted therapies were more effective when matched to individual symptoms, with 29% of patients benefiting from treatments such as CPAP and modafinil.
A new, minimally invasive procedure called Descemet stripping has shown promise in treating Fuchs endothelial dystrophy (FED), a common eye disease. The procedure restored clear vision to three out of four patients without the need for corneal transplants.
A joint research group found RNA abnormalities in the sodium channel in the heart as the cause of heart arrhythmia in myotonic dystrophy. This discovery will help prevent death and develop new treatments for the disease. Abnormalities in RNA splicing lead to various conditions, including cardiac sodium channel dysfunction.
Myotonic dystrophy causes wasting of skeletal muscles and arrhythmia due to mutated RNA sequences that alter gene regulation. Researchers identify altered SCN5A splicing as key factor in cardiac dysfunctions, paving way for potential treatment restoration of normal heart function.
A new study has pinpointed the symptoms of rare myotonic dystrophy type 2 (DM2) that are most important to patients. The research, published in Neurology, found that fatigue and pain were key concerns for DM2 patients.
Researchers have pinpointed the genetic cause of a rare form of blindness, which can present itself as a key-hole shaped defect in the eye. The miR-204 gene mutation has been linked to inherited retinal dystrophy associated with ocular coloboma.
A potential treatment for myotonic muscular dystrophy has been identified, using an experimental drug that improves muscle function and reduces symptoms in mice. The therapy targets excessive activity of a cellular protein called TWEAK and its receptor Fn14, which correlates with disease severity.
Researchers found that myotonic dystrophy type 1 disrupts the normal control of gene expression in heart tissue, specifically affecting microRNAs. This disruption leads to abnormal protein activity, resulting in disease symptoms such as heart malfunction and death.
Researchers at Scripps Research Institute have discovered the atomic-level structure of a genetic defect causing myotonic dystrophy type 2, allowing them to design compounds that improve disease-associated defects in treated cells. The study's findings hold promise for treating this rare form of muscular dystrophy.
Researchers found aberrant splicing changes the form of an enzyme involved in metabolism, leaving slow muscle fibers unable to sustain exercise. This discovery may explain the muscle wasting seen in myotonic dystrophy, a disease characterized by abnormal CTG repeats.
Researchers at the University of Illinois have developed a small molecule that breaks up protein-RNA clusters causing muscular dystrophy, offering hope for treatment. The compound targets only the repeating RNA sequence, increasing regulatory activity and breaking up disease-causing clusters.
A novel drug delivery strategy has been shown to neutralize mutant RNA toxicity and eliminate myotonia symptoms in mice with myotonic dystrophy. The approach uses antisense oligonucleotides and peptide-linked morpholino oligonucleotides to target the disease-causing mutation.
Research reveals that the amount of protein in solution determines the formation of fibrils, which can lead to cell death. Developing treatments for diseases caused by protein aggregation is a possibility with this new knowledge.
Researchers from IRCM, MIT, USC, and Illumina have made a significant breakthrough in the fight against muscular dystrophies, particularly myotonic dystrophy. The study provides insights into the role of muscleblind-like proteins in causing the disease and has potential applications for diagnostic tools and treatment.
A new mouse model has reproduced key cognitive and behavioral symptoms of myotonic dystrophy, a disease marked by progressive muscle wasting and weakness. The study reveals that molecular missteps disrupt brain function, causing toxic RNAs to produce incorrect proteins in the brain.
Researchers have reversed symptoms of myotonic muscular dystrophy in mice by targeting and eliminating toxic RNA in muscle cells. The treatment approach has shown significant promise, reducing symptoms by up to one year in a mouse model.
A new study reveals that myotonic dystrophy patients prioritize fatigue, mobility, and sleep problems over symptoms like myotonia, which are often considered hallmark symptoms. Researchers have developed a patient-reported outcome measure to better evaluate the impact of experimental therapies on patients' lives.
Researchers have identified a genetic factor called a trinucleotide repeat as a strong predictor of Fuchs' dystrophy. The study found that unusually long segments of repeated DNA nucleotides in the TCF4 gene cause havoc, impacting the coding of the protein.
Researchers found that corneal thickening occurs in FECD patients before swelling is observed, necessitating regular monitoring and potential surgical intervention. The study's findings have the potential to improve patient care for Fuchs corneal dystrophy.
A study found that invasive treatment strategies, including heart testing and pacemaker implantation, can increase survival rates for patients with myotonic dystrophy type 1. The treatment approach resulted in a lower incidence of sudden death and improved overall survival.
Myotonic dystrophy is caused by a mutation that causes toxic RNA to accumulate in cells. Antisense oligonucleotides have been shown to be effective in cell culture and mice by degrading the toxic RNA. The treatment will need to be refined for systemic delivery to patients with myotonic dystrophy.
Researchers designed a series of small molecules that target an RNA defect causing myotonic dystrophy type 1. These compounds improve biological defects in cell culture and animal models by more than 40 percent.
A new surgical strategy using a single donor cornea can successfully treat two patients with different corneal diseases, such as Fuchs' dystrophy and keratoconus. The approach may nearly double the available corneal tissue supply and make timely treatment available to many more patients.
Researchers at the University of Rochester Medical Center found that mexiletine is effective in alleviating myotonia, a central symptom of myotonic dystrophy. The medication reduces muscle stiffness and relaxation time by 38-59% in patients with the condition.
Scientists studying fruit flies have discovered a critical step in fly vision that is also linked to human retinal dystrophies, which cause visual impairments or blindness. The study's findings suggest that using flies as a model organism can lead to the development of new therapies for treating human retinal degeneration.
Researchers at the University of Oregon and University of Rochester discovered a compound that reverses genetic defects in RNA leading to type 1 myotonic dystrophy. The compound, pentamidine, disrupts complexes formed by expanded repeats and protein molecules, allowing proper splicing errors to be rescued.
Researchers found a synthetic molecule that breaks up deposits of toxic genetic material and re-establishes cellular activity disrupted by myotonic dystrophy. The treatment could restore muscle function in people with the disease.
A multicenter study has identified risk factors for sudden death in people with myotonic dystrophy type 1, a common form of muscular dystrophy. The study found that patients with significant ECG abnormalities were at a 3.5 times higher risk of sudden death, while those with atrial arrhythmias had a 5 times higher risk.
Researchers at the University of Rochester Medical Center have identified a synthetic RNA-based molecule that eliminates myotonia, a symptom of muscular dystrophy, in mice. The study restored normal muscle function by re-establishing a critical cellular mechanism that controls electrical activity in muscles.
Researchers at the University of Oregon have identified the normal functioning of an RNA-regulating protein called muscleblind, which helps explain how myotonic dystrophy disease occurs. The study found that muscleblind binds to both normal and toxic forms of RNA, highlighting a key clue to understanding the disease.